Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Neuvotion, Inc. is an early-stage medical device company developing AI-driven neuromodulation technologies and products for use in the neurorehabilitation, brain-computer interface (BCI), and physical ...

Surgery: Your doctor may recommend this treatment to remove tumors or other growths on your skin. This is an aggressive treatment. To have a stem cell transplant, you must have a donor who can give ...

Spinal muscle atrophy or SMA is a genetic disease that gradually destroys motor neurons, nerve cells in the spinal cord that control muscles. That leads muscles to waste away, especially in the legs, ...

With only pharmacological treatments ... in cell transplantation and bioactive molecule delivery to the injured CNS, with specific focus on the brain and spinal cord after traumatic injury ...

Objectives Traumatic and non-traumatic spinal cord ... the injury, grey matter atrophy lagged initially behind white matter neurodegeneration, in the lumbar enlargement these processes progressed in ...

The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment ... approved and registered case series on the effect of MSC therapy in arthritis. A ...

The treated cells are then returned to the patient via an infusion. It is estimated that around 50 patients, suitable for a stem cell transplant but without a matched donor, will receive the ...

Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi ... Brothers specializes in neuro-musculoskeletal treatments. The transaction for the U.S. business is set to close ...